 The purpose of this study is to determine the overall survival of patients diagnosed with Stage 3b or 4 non-small cell lung cancer NSCLC treated with an oral Farnesyl Protein Transferase Inhibitor LonafarnibSCH 66336 in combination with paclitaxel and carboplatin with that of patients treated with placebo in combination with paclitaxel and carboplatin. 